One popular pill may not live up to its claims of shedding pounds and busting belly fat, according to a new study.

Topline data from the phase 3 ATTAIN-MAINTAIN trial evaluated orforglipron for weight maintenance after initial treatment with Wegovy or Zepbound in adults with obesity or overweight.

A once-weekly injectable GIP/GLP-1 dual agonist conferred up to 22.5% weight loss at 48 weeks for adults with overweight or ...

Many people who stop using weight loss drugs will return to their previous weight within two years, a new review of existing research has found. This rate of weight regain is significantly faster than ...

Year after year, Mary Bucklew strategized with a nurse practitioner about losing weight. “We tried exercise,” like walking 35 minutes a day, she recalled. “And 39,000 different diets.” But 5 pounds ...

If you’re looking to create a healthier lifestyle, look no further than the power of running. Movement makes up a portion of the weight loss puzzle, and with our new Running for Weight Loss program, ...

Share on Pinterest The Food and Drug Administration (FDA) recently approved a tablet version of the GLP-1 drug Wegovy for weight loss. Image courtesy of Novo Nordisk Novo Nordisk officials said a new ...

New York Post may be compensated and/or receive an affiliate commission if you click or buy through our links. Featured pricing is subject to change. January has a funny way of making us ambitious.

A pill form of weight-loss drug Wegovy, manufactured by Danish drugmaker Novo Nordisk, is now available in the U.S., giving Americans access to an oral medication to treat obesity. The starting dose ...

Noom Med is a medically-guided weight loss program that combines clinical care with Noom's behavior-change tools. The program provides virtual consultations, medication management, and nutrition ...

Running for weight loss is as much of a mental journey as it is a physical one. Oftentimes, it’s a process that puts too much emphasis on the number on the scale, which can result in feelings of low ...

GLP-1 medications have dominated the weight-loss landscape this year — but some older Americans are reportedly kicking the trend to the curb. A study published in JAMA in January 2025 — which looked ...